New phase 3 data show that sacituzumab govitecan plus pembrolizumab delays cancer progression in PD-L1-positive metastatic ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

A new smartphone app can accurately estimate hemoglobin levels and screen for anemia, just by analyzing a photo of your ...

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...

MEVPRO-2 (NCT06629779) is a global, randomized, double-blind, placebo‑controlled phase III trial in ARPI-naïve mCRPC patients. The key inclusion and exclusion criteria are detailed in the table below.

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...